Association between polymorphisms in human tumor necrosis factor-alpha (-308) and -beta (252) genes and development of gestational diabetes mellitus

Diabetes Research and Clinical Practice

Volumn 88, Issue 2, 2010, Pages 139-145

  Montazeri, Shabnam ^a   Nalliah, Sivalingam ^a   Radhakrishnan, Ammu Kutty ^a  

^a INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

Cytokine; Gestational diabetes mellitus (GDM); Single nucleotide polymorphism; TNF ; TNF

Indexed keywords

ADENINE; GUANINE; INSULIN; LYMPHOTOXIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CONTROLLED STUDY; DIABETIC DIET; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RISK; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; PREGNANCY DIABETES MELLITUS; PROMOTER REGION; PROTEIN BLOOD LEVEL; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM;

ADOLESCENT; ADULT; CASE-CONTROL STUDIES; DIABETES, GESTATIONAL; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; LYMPHOTOXIN-ALPHA; POLYMORPHISM, SINGLE NUCLEOTIDE; PREGNANCY; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

EID: 77952884174     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.01.028     Document Type: Article

References (39)

1. Diagnosis and Classification of Diabetes Mellitus. Report of a WHO Consultation 1999, World Health Organization, Department of Non-communicable Disease Surveillance, Geneva.
2. Metzger B.E. Summary and recommendation of the third International work shop: conference on gestational diabetes mellitus. Diabetes 1991, 40:197-202.
3. Luesley D.M., Baker P.N. Obstetrics and Gynecology, Evidence Based Text for MRCOG 2004, Arnold Publication, London, pp. 172-174.
4. Winkler G., Cseh K., Baranyi E., Melczer Z., Speer G., Hajos P., et al. Tumor necrosis factor system in insulin resistance in gestational diabetes. Diabetes Res. Clin. Pract. 2002, 56(2):93-99.
5. Greenberg A.S., McDaniel M.L. Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipose-derived cytokines in the pathogenesis of type 2 diabetes. Eur. J. Clin. Invest. 2000, 32:24-34.
6. Warle M.C., Farhan A., Metselaar H.J., Hop W.C., Perrey C., zondervan P.E., et al. Are cytokine gene polymorphisms related to in vitro cytokine production profile?. Liver Transplant. 2003, 9(2):170-181.
7. Kubaszek A., Pihlajamäki J., Komarovski V., Lindi V., Lindström J., Eriksson J., et al. Promoter polymorphisms of the TNF-α (G-308A) and IL-6 (C-174G) genes predict the conversion from impaired glucose tolerance to type 2 diabetes. Diabetes 2003, 52:1872-1876.
8. Dandona P., Weinstock R., Thusu K., Abdel-Rahman E., Aljada A., Wadden T. Tumor necrosis factor-alpha in sera of obese patients: fall with weight loss. J. Clin. Endocrinol. Metab. 1998, 83:2907-2910.
9. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol. Immunol. 1997, 34:391-399.
10. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff G.W. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:3195-3199.
11. Bouma G., Crusius J.B., Oudkerk Pool M., Kolkman J.J., von Blomberg B.M., Kostense P.J., et al. Secretion of tumour necrosis factor alpha and lymphotoxin alpha in relation to polymorphisms in the TNF genes and HLA-DR alleles: relevance for inflammatory bowel disease. Scand. J. Immunol. 1996, 43:456-463.
12. Fernandez-Real J., Gutierrez C., Ricart W., Casamitjana R., Fernandez-Castaner M., Vendrell J., et al. The TNFalpha gene Nco I polymorphism influences the relationship among insulin resistance, percent body fat, and increased serum leptin levels. Diabetes 1997, 46:1468-1472.
13. Dalziel B., Gosby A.K., Richman R.M., Bryson J.M., Caterson I.D. Association of the TNF-alpha -308 G/A promoter polymorphism with insulin resistance in obesity. Obes. Res. 2002, 10:401-407.
14. Koch M., Rett K., Volk A., Maerker E., Haist K., Weisser M., et al. The tumor necrosis factor alpha -238 G→A and -308 G→A promoter polymorphisms are not associated with insulin sensitivity and insulin secretion in young healthy relatives of type 2 diabetic patients. Diabetologia 2000, 43:181-184.
15. Rusmusse S.K., Urhammer S.A., Jensen J.N. The polymorphism of the tumor necrosis factor alpha gene promoter are not associated with features of the insulin resistance syndrome or altered birth weight in Danish Caucasians. J. Clin. Endocrinol. Metab. 2000, 85:1731-1734.
16. Um J.Y., Hyung-Mn Kim H.M. Frequencies of the tumor necrosis factor polymorphisms in the Korean population. Hereditas 2003, 139:184-188.
17. Casano-Sancho P., Lopez-Bermejot A., Frenandez-Real J.M., Monros E., Valls C., Rodriguez-Gonzalez F., et al. The tumour necrosis factor (TNF)-a -308GA promoter polymorohism is related to prenatal growth and postnatal insulin resistance. Clin. Endocrinol. 2006, 64:129-135.
18. Stanulla M., Schrauder A., Welt K., Schrape M. Tumour necrosis factor and lymphotoxin-alpha genetic polymorphisms and risk of relapse in childhood B-cell acute lymphoblastic leukaemia. BMC Blood Disord. 2001, 1(2):1-6.
19. Porter A.G. Human tumor necrosis factor-alpha and -beta: differences in their structure, expression and biological properties. FEMS Microbiol. Immunol. 1990, 2(4):193-199.
20. Takashige N., Naruse T.K., Matsumori A., Hara M., Nagai S., Moromoto S., et al. Genetic polymorphisms at the tumour necrosis factor loci (TNFA and TNFB) in cardiac sarcoidosis. Tissue Antigens 1999, 54:191-193.
21. Fei B.Y., Deng C.S., Xia B., You-Qing Z., Bart A.C., Salvador P.A. Polymorphisms at the TNF locus in Chinese Han population. Hum. Immunol. 2002, 63:71-75.
22. Lee S.C., Pu Y.B., Thomas G.N., Leee Z.S.K., Tomlinson B., Cockram S., et al. Tumor necrosis factor alpha gene G-308A polymorphism in the metabolic syndrome. Metabolism 2000, 49:1021-1024.
23. Hoffstedt J., Eriksson P., Helllstrom L., Rossner S., Ryden M., Arner P. Excessive fat accumulationis associated with the TNF α -308 G/A promoter polymorphism in women but not in men. Diabetologia 2000, 43:117-120.
24. Herrmann S.M., Ricard S., Nicaud V., Mallet C., Arveiler D., Evince A., et al. Polymorphisms of the tumour necrosis factor-alpha gene, coronary heart disease and obesity. Eur. J. Clin. Invest. 1998, 28:59-66.
25. Brand E., Schorr U., Kunz I., Kertmen E., Ringel J., Distler A., et al. Tumor necrosis factor-alpha -308 G/A polymorphism in obese Caucasians. Int. J. Obs. Relat. Metab. Disord. 2001, 25:581-585.
26. Howell W.M., Turner S.J., Collins A., Bateman A.C., Theaker J.M. Influence of TNFalpha and LTalpha single nucleotide polymorphisms on susceptibility to and prognosis in cutaneous malignant melanoma in the British population. Eur. J. Immunogenet. 2002, 29:17-23.
27. Dalziel B., Gosby A.K., Richman R.M., Bryson J.M., Caterson I.D. Association of the TNF a -308 G/A promoter polymorphism with insulin resistance in obesity. Obes. Res. 2002, 10:401-407.
28. Shiau M.Y., Wu C.Y., Huang C.N., Hu S.W., Lin S.J., Chang Y.H. TNF α polymorphisms and type 2 diabetes mellitus in Taiwanese patients. Tissue Antigens 2003, 61(5):393-399.
29. Walston J., Seibert M., Yen C.J., Cheskin L.J., Andersen R.E. Tumor necrosis factor-alpha -238 and -308 polymorphisms do not associated with traits related to obesity and insulin resistance. Diabetes 1999, 48:2096-2098.
30. Kirwan J., Mouzon S., Lepercq J., Challier J., Huston-Presley L., Friedman J., et al. TNF-α is a predictor of insulin resistance in human pregnancy. Diabetes 2002, 51:2207-2213.
31. Vince G.S., Johnson P.M. Is there a TH2 bias in human pregnancy?. J. Reprod. Immunol. 1996, 32:101-104.
32. Hotamisligil G.S., Budavari A., Murray D., Spiegelman B.M. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha. J. Clin. Invest. 1993, 94:1543-1549.
33. Hotamisligil G.S., Shargill N.S., Spiegelman B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science 1994, 259:87-91.
34. Tsiotra P.C., Tsigos C., Raptis S.A. TNFalpha and leptin inhibit basal and glucose-stimulated insulin secretion and gene transcription in the HIT-T15 pancreatic cells. Int. J. Obes. Relat. Metab. Disord. 2001, 25:1018-1026.
35. Hotamisligil G.S., Arner P., Caro J.F., Atkinson R.L., Spiegelman B.M. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J. Clin. Invest. 1995, 95:2409-2415.
36. Stephens J.M., Lee J., Pilch P.F. Tumor necrosis factor alpha induced insulin resistance in 3T3-L1 adipocytes is accompanied by a loss of insulin receptor substrate-1 and GLUT-4 expression without a loss of insulin-receptor-mediated transduction. J. Biol. Chem. 1997, 272:971-976.
37. Ofei F., Hurel S., Newkirk J., Sopwith M., Taylor R. Effects of an engineered human anti-TNF-α antibody (CDP571) on insulin sensitivity and glycemic control in patients with NIDDM. Diabetes 1996, 45:881-885.
38. Bluher M., Kratzsch J., Paschke R. Plasma levels of tumor necrosis factor-α, angiotensin II, growth hormone and IGF-I are not elevated in insulin-resistant obese individuals with impaired glucose tolerance. Diabetes Care 2001, 24:328-334.
39. Mclachlan K.A., O'Neal D., Jenkins A., Alford F.A. Do Adiponectin, TNF-α, leptin and CRP relate to insulin resistance in pregnancy? Studies in women with and without gestational diabetes, during and after pregnancy. Diabetes Metab. Res. Rev. 2006, 22:131-138.